Hydroxyurea potentiates the antiherpesvirus activities of purine and pyrimidine nucleoside and nucleoside phosphonate analogs

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 12, 1999, Pages 2885-2892

  Neyts, J ^a   De Clercq, E ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

5 (2 BROMOVINYL) 2' DEOXYURIDINE; 9 [4 HYDROXY 2 (HYDROXYMETHYL)BUTYL]GUANINE; ACICLOVIR; ADEFOVIR; CIDOFOVIR; DNA POLYMERASE; GANCICLOVIR; HYDROXYUREA; LOBUCAVIR; NUCLEOSIDE TRIPHOSPHATE; PENCICLOVIR; PURINE NUCLEOSIDE DERIVATIVE; PYRIMIDINE NUCLEOSIDE DERIVATIVE; THYMIDINE KINASE; VIRUS DNA;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DRUG ACTIVATION; DRUG CYTOTOXICITY; DRUG POTENTIATION; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HERPES VIRUS; NONHUMAN; PRIORITY JOURNAL; VERO CELL;

EID: 0032795831     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.12.2885     Document Type: Article

References (32)

1. Baba, M., R. Pauwels, J. Balzarini, P. Herdewijn, E. De Clercq, and J. Desmyter. 1987. Ribavirin antagonizes inhibitory effects of pyrimidine 2′,3′-dideoxynucleosides but enhances inhibitory effects of purine 2′,3′-dideoxynucleosides on replication of human immunodeficiency virus in vitro. Antimicrob. Agents Chemother. 31:1613-1617.
2. Balzarini, J., and E. De Clercq. 1991. 5-Phosphoribosyl 1-pyrophosphate synthetase converts the acyclic nucleoside phosphonates 9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine and 9-(2-phosphonylmethoxyethyl)adenine directly to their antivirally active diphosphate derivatives. J. Biol. Chem. 266:8686-8689.
3. Biron, F., F. Lucht, D. Peyramond, A. Fresard, T. Vallet, F. Nugier, J. Grange, S. Malley, F. Hamedi-Sangsari, and J. Vila. 1995. Anti-HIV activity of the combination of didanosine and hydroxyurea in HIV-1-infected individuals. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 10:36-40.
4. Charache, S. 1997. Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Semin. Hematol. 34:15-21.
5. De Clercq, E. 1995. Trends in the development of new antiviral agents for the chemotherapy of infections caused by herpesviruses and retroviruses. Rev. Med. Virol. 5:149-164.
6. De Clercq, E., J. Descamps, G. Verhelst, R. T. Walker, A. S. Jones, P. F. Torrence, and D. Shugar. 1980. Comparative efficacy of different antiherpes drugs against different strains of herpes simplex virus. J. Infect. Dis. 141: 563-574.
7. De Clercq, E., A. Holý, I. Rosenberg, T. Sakuma, J. Balzarini, and P. C. Maudgal. 1986. A novel selective broad-spectrum anti-DNA virus agent. Nature 323:464-467.
8. De Clercq, E., T. Sakuma, M. Baba, R. Pauwels, J. Balzarini, I. Rosenberg, and A. Holý. 1987. Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. Antivir. Res. 8:261-272.
9. Deeks, S. G., A. Collier, J. Lalezari, A. Pavia, D. Rodrigue, W. L. Drew, J. Toole, H. S. Jaffe, A. S. Mulato, P. D. Lamy, W. Li, J. M. Cherrington, N. Hellmann, and J. Kahn. 1997. The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled trial. J. Infect. Dis. 176:1517-1523.
10. Donehowever, R. C. 1992. An overview of the clinical experience with hydroxyurea. Semin. Oncol. 19(Suppl. 9):11-19.
11. Dunkle, L. M. 1998. Lobucavir: new broad-spectrum antiviral agent, p. 1-5. In D. M. Sapienza (ed.), Antivirals, latest preclinical and clinical developments for infectious diseases. International Business Communications, Inc., Southborough, Mass.
12. Gao, W.-Y., D. G. Johns, and H. Mitsuya. 1994. Anti-human immunodeficiency virus type 1 activity of hydroxyurea in combination with 2′,3′-dideoxynucleosides. Mol. Pharmacol. 46:767-772.
13. Gao, W.-Y., D. G. Johns, S. Chokekijchai, and H. Mitsuya. 1995 Disparate actions of hydroxyurea in potentiation of purine and pyrimidine 2′,3′-dideoxynucleoside activities against replication of human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 92:8333-8337.
14. Gao, W.-Y., H. Mitsuya, J. S. Driscoll, and D. G. Johns. 1995. Enhancement by hydroxyurea of the anti-human immunodeficiency virus type 1 potency of 2′-β-fluoro-2′,3′-dideoxyadenosine in peripheral blood mononuclear cells. Biochem. Pharmacol. 50:274-276.
15. Johns, D. G., and W.-Y. Gao. 1998. Selective depletion of DNA precursors. An evolving strategy for potentiation of dideoxynucleoside activity against human immunodeficiency virus. Biochem. Pharmacol. 55:1551-1556.
16. Lori, F., A. Malykh, A. Caran, D. Sun, J. N. Weinstein, J. Lisziewicz, and R. C. Gallo. 1994. Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science 266:801-805.
17. Lowe, D. M., W. K. Alderton, M. R. Ellis, V. Parmar, W. H. Miller, G. B. Roberts, J. A. Fjfe, R. Gaillard, P. Ertl, W. Snowden, and E. Liltler. 1995. Mode of action of (R)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine against herpesviruses. Antimicrob. Agents Chemother. 39:1802-1808.
18. Malley, S. D., J. M. Grange, F. Hamedi Sangsari, and J. R. Vila. 1994. Synergistic anti-human immunodeficiency virus type 1 effect of hydroxamate compounds with 2′,3′-dideoxyinosine in infected resting human lymphocytes. Proc. Natl. Acad. Sci. USA 91:11017-11021.
19. Montaner, J. S. G., C. Zala, B. Conway, J. Raboud, P. Patenaude, S. Rae, M. V. O'Shaughnessy, and M. T. Schechter. 1997. A pilot study of hydroxyurea among patients with advanced human immunodeficiency virus (HIV) disease receiving chronic didanosine therapy: Canadian HIV trials network protocol 080. J. Infect. Dis. 175:801-806.
20. Naesens, L., R. Snoeck, G. Andrei, J. Balzarini, J. Neyts, and E. De Clercq. 1997. HPMPC (cidofovir). PMEA (adefovir) and related acyclic nucleoside phosphonate analogues: a review of their pharmacology and clinical potential in the treatment of viral infections. Antivir. Chem. Chemother. 8:1-23.
21. Neyts, J., and E. De Clercq. 1998. Mycophenolate mofetil strongly potentiates the antiherpesvirus activity of acyclovir. Antivir. Res. 40:53-56.
22. Neyts, J., and E. De Clercq. 1999. The immunosuppressive agent mycophenolate mofetil markedly potentiates the activity of Lobucavir [1R(1α,2β3α)]-9-[2,3-bis(hydroxymethyl)-cyclobutyl]guanine against different herpesviruses. Transplantation 67:760-764.
23. Neyts, J., G. Andrei, and E. De Clercq. 1998. The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of acyclovir, ganciclovir, and penciclovir in vitro and in vivo. Antimicrob. Agents Chemother. 42:216-222.
24. Neyts, J., G. Andrei, and E. De Clercq. 1998. The antiherpesvirus activity of H2G [(R)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine] is markedly enhanced by the novel immunosuppressive agent mycophenolate mofetil. Antimicrob. Agents Chemother. 42:3285-3289.
25. Palmer, S., and S. Cox. 1997. Increased activation of the combination of 3′-azido-3′-deoxythymidine and 2′-deoxy-3′-thiacytidine in the presence of hydroxyurea. Antimicrob. Agents Chemother. 41:460-464.
26. Palmer, S., R. W. Shafter, and T. C. Merigan. 1999. Hydroxyurea enhances the activities of didanosine, 9-[2-(phosphonylmethoxy)ethyl]adenine, and 9-[2-(phosphonylmethoxy)propyl]adenine against drug-susceptible and drug-resistant human immunodeficiency virus isolates. Antimicrob. Agents Chemother. 43:2046-2050.
27. Ransom, J. T. 1995. Mechanism of action of mycophenolate mofetil. Ther. Drug Monit. 17:681-684.
28. Rutschmann, O. T., M. Opravil, A. Iten, R. Malinverni, P. L. Vernazza, H. C. Bucher, E. Bernasconi, P. Sudre, D. Leduc, S. Yerly, L. H. Perrin, B. Hirschel, and the Swiss HIV Cohort Study. 1998. A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. AIDS 12:F71-F77.
29. Tenney, D. J., G. Yamanaka, S. M. Voss, C. W. Cianci, A. V. Tuomari, A. K. Sheaffer, M. Alam, and R. J. Colonno. 1997. Lobucavir is phosphorylated in human cytomegalovirus-infected and -uninfected cells and inhibits the viral DNA polymerase. Antimicrob. Agents Chemother. 41:2680-2685.
30. Vila, J., F. Nugier, G. Barguès, et al. 1997. Absence of viral rebound after treatment of HIV-infected patients with didanosine and hydroxycarbamide. Lancet 348:203-204.
31. Xiong, X., J. L. Smith, C. Kim, E. S. Huang, and M. S. Chen. 1996. Kinetic analysis of the interaction of cidofovir diphosphate with human cytomegalovirus DNA polymerase. Biochem. Pharmacol. 51:1563-1567.
32. Xiong, X., J. L. Smith, and M. S. Chen. 1997. Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation. Antimicrob. Agents Chemother. 41:594-599.